RAR/RXR
Retinoic acid receptors; Retinoid X receptors
The nuclear retinoic acid receptors (RARs) are transcriptional transregulators, which control the expression of specific gene subsets subsequently to ligand binding and to strictly controlled phosphorylation processes. RARs consist of three subtypes, α (NR1B1), β (NR1B2) and γ (NR1B3), encoded by separate genes. RARs function as ligand-dependent transcriptional regulators, heterodimerized with retinoid X receptors (RXRs), which also consist of three types, α NR2B1, β (NR2B2) and γ (NR2B3). RARs play critical roles in a variety of biological processes, including development, reproduction, immunity, organogenesis and homeostasis, as assessed by vitamin A-deficiency (VAD), pharmacological and genetic studies conducted in the mouse.
Retinoid X receptor (RXR) belongs to a family of ligand-activated transcription factors that regulate many aspects of metazoan life. A class of nuclear receptors requires RXR as heterodimerization partner for their function.
RAR/RXR Isoform Specific Products
All Product Categories
-
RAR/RXR Related Products (217)
Related Products (217)
-
Antibodies (1)
-
RAR/RXR Isoform Comparison
-
Hydroxypinacolone retinoate
0 ImagesSynonyms: HPRHydroxypinacolone retinoate (HPR) is a direct-binding agonist of retinoic acid receptor (RAR). Hydroxypinacolone retinoate has low irritation and high stability; when formulated into nanoparticles, its transdermal efficiency is enhanced, allowing it to penetrate deep into the dermis and achieve sustained release. When used in combination with Retinyl propionate, hydroxypinacolone retinoate promotes fibroblast proliferation and upregulates the gene expression of type IV collagen, CRBP-I and RARB. Hydroxypinacolone retinoate can be used in research related to skin wrinkles and skin aging.
-
PROTAC RAR Degrader-1
0 ImagesCat. No.: HY-111844CAS No.: 1351169-27-1PROTAC RAR degrader-1 (Compound 9) is a potent and selective RAR PROTAC Degrader consisting of apoptotic protein inhibitors (IAPs) ligands. IAPs-based degraders are also known as SNIPERs. PROTAC RAR Degrader-1 reduces RARα levels in HT1080 cells in a concentration-dependent manner but is blocked by the proteasome inhibitor MG132 (HY-13259). PROTAC RAR Degrader-1 can be used in the study of nuclear receptor-related diseases. (Pink: RAR ligand 1 (HY-111843); Black: Linker (HY-140189); Blue: IAPs Ligand (HY-B0134)).
-
Liarozole dihydrochloride
0 ImagesSynonyms: R75251 dihydrochlorideLiarozole (R75251) dihydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole dihydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of RA (IC50=7 μM), resulting in increased tissue levels of RA. Liarozole dihydrochloride shows antitumoral properties.
-
DC271
0 ImagesCat. No.: HY-D1190CAS No.: 198696-03-6DC271 is a RAR agonist and synthetic retinoid that binds to the retinoid-binding site of cellular retinoic acid-binding protein II (CRBP-II). DC271 exhibits solvatochromic fluorescence properties: it produces intense blue-shifted emission in nonpolar environments and weak red-shifted emission in polar environments, and its severe fluorescence quenching in aqueous solutions can be reversed by embedding in the hydrophobic retinoid-binding protein pocket. DC271 enables direct detection of the binding between unlabeled compounds and related retinoid-binding proteins via fluorescence competition assays (Ex/Em = 355 nm/460 nm).
-
RXR antagonist 5
0 ImagesRXR antagonist 5 (compound 22) is a selective retinoic acid X receptor (RXR) antagonist with binding potential to RXR evaluated by modeling.
-
RXR antagonist 1
0 ImagesRXR antagonist 1 (compound 6a) is a retinoid X receptor (RXR) modulator. RXR antagonist 1 shows potent RXR-antagonistic activity, with a pA2 of 8.06. RXR antagonist 1 can be used for type 2 diabetes research.
-
ZSH-2208
0 ImagesZSH-2208 is an analog of retinoic acid A, which exerts a potent antitumor effect on regenerative stem cells (TRCs) of esophageal squamous cell carcinoma (ESCC) through RARγ-TNFAIP3.
-
Arotinoid
0 ImagesSynonyms: Ro 13-6298; Arotinoid ethyl esterArotinoid (RO 13-6298) is a retinoid, and acts as an orally active and highly potent agonist of retinoic acid receptors (RARs) with antipsoriatic effects. Arotinoid has antipapiltoma activity with an ED50 of 0.05 mg/kg. Arotinoid can be used for the research of skin carcinomas.
-
Bexarotene-d4
0 ImagesSynonyms: LGD1069 d4Bexarotene-d4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma.
-
Isotretinoin (Standard)
0 ImagesIsotretinoin (Standard) is the analytical standard of Isotretinoin. This product is intended for research and analytical applications. Isotretinoin (13-cis-Retinoic acid) is an orally active vitamin A derivative and is often be used for the research of severe acne. Isotretinoin also shows anticancer activity.
-
Retinoic acid-d6
0 ImagesCat. No.: HY-14649S3CAS No.: 2483831-72-5Synonyms: Vitamin A acid-d6; all-trans-Retinoic acid-d6; ATRA-d6Retinoic acid-d6 is the deuterium labeled Retinoic acid[1]. Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha[2][3][4][5][6][7].
-
AM580 (GMP)
0 ImagesCat. No.: HY-10475GCAS No.: 102121-60-8Synonyms: CD336 (GMP); NSC608001 (GMP); Ro 40-6055 (GMP)
-
Viaminate
0 ImagesCat. No.: HY-112077ACAS No.: 53839-71-7Viaminate is a derivative of Retinoic acid, which is used for the study of severe acne and other keratinization disorders.
-
16α-Hydroxytrametenolic acid
0 Images16α-Hydroxytrametenolic acid, a natural triterpene, is a potential retinoid X receptor (RXR) selective agonist.
-
(-)-Talarozole
0 Images(-)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.
